Jon Congleton
-
Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test
The Radnor biopharmaceutical firm Mineralys Therapeutics saw its stock price hit new heights Monday after a positive late-stage clinical trial showed promise for its new…
-
Mineralys in Radnor Raises Funds for new Blood Pressure Treatment
Mineralys Therapeutics, a Radnor biopharmaceutical company is hoping to raise $100 million to develop a new high blood pressure treatment, writes John George for Philadelphia…
-
Investors’ Back Radnor Firm’s Development of Blood Pressure Drug
Mineralys Therapeutics in Radnor is getting a $118 million investment from biotech investors in six nations to develop a new blood-pressure drug, writes Joseph N.…
-
Radnor Biopharma Firm Looks at Hormone Targeting to Treat Hypertension
Mineralys Therapeutics in Radnor is on its way to developing a drug that will selectively treat hypertension, writes Laura Brzyski for Philadelphia Magazine. Mineralys Therapeutics…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
